Direct answer
What you need to know
Evidence strength: StrongSince 2026-07-01, eligible Medicare Part D enrollees can get certain weight-management GLP-1 medications for a flat $50 a month. That is significant because Part D has historically been unable to cover medications prescribed solely for weight loss. But plan participation is voluntary, the exact formulation matters, and the $50 counts toward neither your deductible nor your out-of-pocket cap.
Key takeaways
- A flat $50/month on covered products, for eligible Part D enrollees.
- Your plan may simply not take part — participation is voluntary, so ask first.
- The device matters: Zepbound single-dose pens and Zepbound vials are excluded.
- Manufacturer savings cards remain unavailable to you — this replaces nothing, it adds a route.
Important limitation: This is a time-limited programme with a successor model planned, and published summaries differ on the end date. Confirm the current position with Medicare and with your own plan rather than relying on any summary, including this one.
Next action: Ask your Part D plan one question before anything else: does it participate? Everything below only matters if the answer is yes.
Primary sources: Medicare.gov, Centers for Medicare & Medicaid Services, DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration
General education, not medical or financial advice. Coverage rules change; verify with Medicare and your plan.
Which products are covered — and which are not
This is the part that catches people out, because the exclusions are not by drug but by formulation. The same molecule in a different device can fall outside the programme.
| Status | Formulation |
|---|---|
| Covered | Wegovy (injection or tablet) |
| Covered | Zepbound (KwikPen only) |
| Covered | Foundayo (tablet) |
| Not covered | Zepbound single-dose pens |
| Not covered | Zepbound vials |
Same drug, different device, different answer. Check which formulation your prescription specifies before you assume the programme applies.
The three eligibility conditions
- Enrolment in a participating Medicare Part D plan
- BMI of 35 or higher, or BMI of 27 or higher with a qualifying related condition
- Prior authorisation
The first is the one to check first, and it is the one nobody expects to fail on. A plan that covers your other medications perfectly well may simply not have opted into this programme.
Four caveats that change what it is worth
Participation is voluntary
Participation is voluntary for Part D plans — your plan may not take part.
It does not count toward your deductible or cap
The $50 does not count toward your Part D deductible or your annual out-of-pocket cap.
Low-income subsidies cannot be applied
Part D low-income subsidies cannot be applied to bridge-programme prescriptions.
The programme is time-limited
This is a time-limited programme with a successor model planned — confirm the current end date with your plan.
The second caveat is the one most likely to surprise you later rather than sooner. Paying $50 a month for twelve months does not move you toward your out-of-pocket maximum, so it does not accelerate the point at which your other medications get cheaper.
What this does not replace
Federal rules prohibit manufacturers from offering copay or savings cards to people with government insurance, and the Bridge does not change that. It sits alongside the other routes that remain open to you: Medicare’s Extra Help programme, state pharmaceutical assistance programmes, and manufacturer patient-assistance programmes, which are means-tested and separate from savings cards.
How those compare against paying cash, and against every other route, is set out on the cheapest way to get a GLP-1 — where the Bridge is priced beside manufacturer-direct self-pay and the telehealth options. The wider coverage picture, including appeals, is on cost and coverage.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Medicare GLP-1 Bridge: GLP-1 drugs for $50 a monthMedicare.gov, Centers for Medicare & Medicaid ServicesSupports: Every figure on this page: the $50 monthly cost, the covered and excluded formulations, the eligibility conditions, and the programme caveats. Verified 2026-07-25.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The formulations named — which product is a KwikPen, a single-dose pen, a vial, or a tablet.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and dosage form for each covered product.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.